Opinion: how patients have benefited from mouse models of acute promyelocytic leukaemia.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 16175176.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
One of the challenges of studying anticancer therapies is that effects observed in cell lines or mouse models are not always good indicators of clinical trial results. The mouse model of acute promyelocytic leukaemia has bucked this trend, as targeted therapies such as retinoic acid and arsenic induce differentiation and clearance of leukaemia cells in both mice and humans. This mouse model has also provided important mechanistic insights into the combinatorial effects of these agents and has promoted combined therapies that have shown recent success in the clinic.
Medical subject headings
- Disease Models, Animal
- Leukemia, Promyelocytic, Acute